Crowelab

Bibliography

Original Reports

1. Barbas CF III, Crowe JE Jr, Cababa D, Jones TM, Zebedee SL, Murphy BR, Chanock RM, Burton DR. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proceedings of the National Academy of Sciences USA 1993; 89: 10164-8.

2. Crowe JE Jr, Barbas CF III, Bui P, Cababa D, Jones TM, Zebedee SL, Murphy BR, Chanock RM, Burton DR. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. In Brown F, Chanock RM, Ginsberg HS, Lerner RA, eds. Vaccines 93: Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory 1993; 7-11.

3. Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993; 11: 1395-404.

4. Crowe JE Jr., Murphy BR, Chanock RM, Williamson RA, Barbas CF III, Burton DR. Recombinant human RSV monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of respiratory syncytial virus-infected mice. Proceedings of the National Academy of Sciences USA 1994; 91: 1386-90.

5. Crowe JE Jr, Bui PT, London WT, Davis AR, Hung PP, Chanock RM, Murphy BR. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1994; 12: 691-700.

6. Crowe JE Jr, Murphy BR, Chanock RM, Williamson A, Barbas CF III, Burton DR. Human RSV monoclonal antibody Fab cloned from a combinatorial library and produced in E. coli is effective therapeutically when introduced directly into the lungs of RSV-infected mice. In Brown F, Chanock RM, Ginsberg HS, Norrby E, eds. Vaccines 94: Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor: Cold Spring Harbor Laboratory Press 1994; 315-20.

7. Crowe JE Jr, Bui PT, Davis AR, Chanock RM, Murphy BR. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus (RSV cpts-248) retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 1994; 12: 783- 90.

8. Crowe JE Jr, Cheung PYK, Wallace E, Larrick JW, Chanock RM, Murphy BR, Fry K. Isolation and characterization of a chimpanzee monoclonal antibody to the G- glycoprotein of respiratory syncytial virus. Clinical and Diagnostic Laboratory Immunology 1994; 1: 701-6.

9. Kulkarni, AB, Collins PL, Bacik I, Yewdell JW, Bennick JR, Crowe JE Jr., Murphy BR. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. Journal of Virology 1994; 69: 1261-4.

10. Hsu K-HL, Crowe JE Jr, Lubeck MD, Davis AR, Hung PP, Chanock RM, Murphy BR. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1NG1 mutant virus. Vaccine 1995; 13: 509-15.

11. Crowe JE Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. Cold- passaged, temperature sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995; 13: 847-55.

12. Connors M, Crowe JE Jr, Firestone CY, Murphy BR, Collins PL. A cold- passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology 1995; 208: 478-84.

13. Crowe JE Jr , Bui PT, Firestone CY, Connors M, Elkins WR, Chanock RM, Murphy BR. Live subgroup B respiratory syncytial virus (RSV) vaccines are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. Journal of Infectious Diseases 1996; 173: 829-39.

14. Crowe JE Jr, Firestone C-Y, Collins PL, Murphy BR. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes 1996; 13: 271-5.

15. Firestone, C.Y., Whitehead, S., Collins, P.L., Murphy, B.R., Crowe, JE Jr. Nucleotide sequence analysis of the respiratory syncytial virus (RSV) subgroup A cold-passaged (cp), temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology 1996; 225: 419-22.

16. Juhasz K, Whitehead SS, Bui PT, Biggs JM, Boulanger CA, Crowe JE Jr, Collins PL, Murphy BR. The temperature-sensitive (ts) phenotype of a cold- passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. Journal of Virology 1997; 71: 5814-9. Byline correction 71: 8953.

17. Karron RA, Wright PF, Crowe JE Jr, Clements ML, Thompson J, Makhene M, Casey R, Murphy BR. Evaluation of two live cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, children and infants. Journal of Infectious Diseases 1997; 176: 1428-36.

18. Crowe JE Jr, Murphy BR, Chanock RM, Duan L, Pomerantz R, Gilmour PS, Pilkington G. Isolation of a second recombinant human respiratory syncytial virus (RSV) monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. Journal of Infectious Diseases 1998; 177: 1073-6.

19. Crowe JE Jr, Firestone C-Y, Beeler JA, Burton DR, Chanock RM, Murphy BR. Monoclonal antibody resistant mutants selected with an respiratory syncytial virus (RSV) neutralizing human antibody Fab fragment (Fab19) define a unique epitope on the fusion (F) glycoprotein. Virology 1998; 252: 373-5.

20. Whitehead SS, Firestone C-Y, Karron RA, Crowe JE Jr., Elkins WR, Collins PL, Murphy BR. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. Journal of Virology 1999; 73: 871-7.

21. Crowe JE Jr, Randolph V, Murphy BR. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo. Virus Research 1999; 59: 13-22.

22. Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM, Burton DR. Human antibody responses to mature and immature forms of viral envelope in RSV infection: Significance for subunit vaccines. Journal of Virology 1999; 73: 2956-62.

23. Pastey MJ, Crowe JE Jr., Graham BS. RhoA Interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. Journal of Virology 1999; 73: 7262-70.

24. Fisher RG, Crowe JE, Johnson TR, Tang YW, Graham BS. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. Journal of Infectious Diseases 1999; 180: 1324 -7.

25. Pastey MJ, Gower TL, Crowe JE Jr., Graham BS. A peptide derived from the respiratory syncytial virus (RSV) fusion glycoprotein binding domain of RhoA inhibits RSV and parainfluenza virus type 3 induced syncytium formation. Nature Medicine 2000; 6: 35-40.

26. Weitkamp J-H, Tang Y-W, Haas DW, Midha NK, Crowe JE Jr. Recurrent Alcaligenes xylosoxidans bacteremia associated with persistent lymph node infection in a patient with Hyper IgM Syndrome. Clinical Infectious Diseases 2000; 31: 1183-7.

27. Peters TR, Brumbaugh DE, Lawton AR, Crowe JE Jr. Recurrent pneumococcal arthritis as the presenting manifestation of X-linked agammaglobulinemia. Clinical Infectious Diseases 2000; 31: 1287-8.

28. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr., Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Casey R, Eichelberger M, Thumar B, Randolph V, Murphy BR. Evaluation of a live, cold-passaged temperature-sensitive, respiratory syncytial virus (RSV) vaccine in infancy. Journal of Infectious Diseases 2000; 182: 1331-42.

29. Crowe JE Jr, Firestone C-Y, Murphy BR. Passively acquired antibodies suppress local and systemic antibody responses, but not cell-mediated protective efficacy, in mice immunized with live attenuated RSV vaccines. Journal of Immunology, 2001; 167:3910-18.

30. Weitkamp J-H, Crowe JE Jr. Blood donor leukocyte reduction filters as a source of human B lymphocytes. Biotechniques 2001; 31: 2-3.

31. Peters TR, Jennings MT, Crowe JE Jr. Pneumocystis carinii pneumonia in a girl with a midbrain glioma. Pediatric Hematology and Oncology, 2002;19:141-3.

32. Brock S, McGraw P, Wright PF, Crowe JE Jr. The human polymeric immunoglobulin receptor facilitates invasion of epithelial cells by Streptococcus pneumoniae in a strain-specific and cell-type specific manner. Infection and Immunity 2002; 70:5091-5.

33. Crowe JE Jr., Sanella EC, Pfeiffer, Zorn G, Azimzadeh A, Miller GG, Newman R, and Pierson RN III. CD154 blockade following cardiac allotransplantation inhibits the humoral immune response to influenza vaccine, American Journal of Transplantation 2003, 3:680-8.

34. Weitkamp J-H, Kallewaard N, Kusuhara K, Feigelstock D, Feng N, Greenberg HB, Crowe JE Jr. Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus- like particles. Journal of Immunological Methods 2003 275:223-37.

35. Venter M, Rock MR, Puren AJ, Tiemessen CT, Crowe JE Jr. Respiratory syncytial virus nucleoprotein-specific cytotoxic T cell epitopes in a South African population of diverse HLA types are conserved in circulating field strains. Journal of Virology 2003; 77:7319-29.

36. Rock MT, Crowe JE Jr. identification of a novel HLA-A*01-restricted CTL epitope in the respiratory syncytial virus fusion protein. Immunology 2003; 108:474-80.

37. Halasa NB, Whitlock JA, McCurley TL, Smith J, Zhu Q, Ochs H, Dermody TS, Crowe JE Jr. Fatal hemophagocytic lymphohistiocytosis associated with Epstein- Barr Virus infection in a patient with a novel mutation in the SLAM-Associated Protein. Clinical Infectious Diseases 2003; 37:E136-41.

38. Weitkamp JH, Kallewaard N, Kusuhara K, Bures E, Williams JV, LaFleur B, Greenberg HB, Crowe JE Jr. Infant and Adult Human B Cell Responses to Rotavirus Share Common Immunodominant Variable Gene Repertoires. Journal of Immunology 2003; 171: 4680-8.

39. Brock S, Goldenring J, Crowe JE Jr. Apical recycling systems regulate directional budding of respiratory syncytial virus from polarized epithelial cells. Proceedings of the National Academy of Sciences USA. 2003; 100:15143-8.

40. Williams JV, Harris P, Pingsterhaus J, Tollefson S, Halburnt-Rush L, Edwards K, Wright P, Crowe JE Jr. Association of human metapneumovirus with lower respiratory tract disease in normal infants and children. New England Journal of Medicine 2004; 350: 443-50.

41. Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE Jr. Adverse events following smallpox immunizations are associated with alterations of systemic cytokine levels. Journal of Infectious Diseases 2004; 189; 1401-1410.

42. Suara RO, Crowe JE Jr. Effect of zinc salts on respiratory syncytial virus replication, Antimicrobial Agents and Chemotherapy 2004; 48:783-90.

43. Kallewaard N, Bowen AL, Crowe JE Jr. Cooperativity of actin and microtubules in RSV replication. Virology. 2004:331: 73-81.

44. Tai JH, Williams JV, Edwards KM,Wright PF, Crowe JE Jr, Dermody TS. Prevalence of reovirus-specific antibody responses in young children in Nashville, TN. Journal of Infectious Diseases, in press.

45. Shaklee JF, Talbot TT, Muldowney JA, Vaughan DE, Butler J, House F, Crowe JE Jr, Smith LH, Edwards KM. Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events. Journal of Infectious Diseases, 2005;191:724-30.

46. Rock MT, Yoder S, Wright PF, Talbot T, Edwards KM, Crowe JE Jr. Differential regulation of granzyme and perforin in effector and memory T cells following smallpox immunization. Journal of Immunology 2005;174:3757-64.

47. Talbot RR, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, Yoder SM, Rock MT, Crowe Jr JE, Edwards KM. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: A randomized trial. Journal of the American Medical Association 2004; 292:1205-12.

48. Weitkamp JH, Kallewaard NL, Bowen AL, Lafleur BJ, Greenberg HB, Crowe JE Jr. VH1-46 Is the Dominant Immunoglobulin Heavy Chain Gene Segment in Rotavirus-Specific Memory B Cells Expressing the Intestinal Homing Receptor alpha 4 beta 7. J Immunol. 2005;174:3454-60.

Invited Reviews

1. Chanock RM, Crowe JE Jr, Murphy BR, Burton DR. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: Potential usefulness in prevention and/or treatment of major human viral diseases. Infectious Agents and Disease 1993; 2: 118-31.

2. Murphy BR, Hall SL, Kulkarni AB, Crowe JE Jr, Collins PL, Connors M, Karron RA, Chanock RM. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Research 1994; 32: 13-36.

3. Murphy BR, Crowe JE Jr, Lubeck MD, Hsu K-HL, Hall SL, Karron RA, Clements ML, Wright PF, Belshe RB, Chanock RM. Live attenuated vaccines for respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV 3). Report of the 104th Ross Conference on Pediatric Research, Ross, 1994, pp 173-8.

4. Crowe JE Jr, Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). Vaccine 1995; 13: 415-21.

5. Crowe J Jr, Wright P, Clements ML, Karron RA, Collins P, Murphy B. Live attenuated respiratory syncytial virus candidates that are satisfactorily attenuated and genetically stable. In: Vaccines, One Hundred Years After Louis Pasteur. The Year of Louis Pasteur International Symposia. Institut Pasteur, Paris, pp 211-13, 1995.

6. Crowe JE Jr. The role of antibodies in respiratory viral immunity. Seminars in Virology 1996; 7: 273-83.

7. Crowe JE Jr. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. Vaccine 1998; 16: 1423-32.

8. Crowe JE Jr. Host responses to respiratory virus infection and immunization. Current Topics in Microbiology and Immunology 1999, volume 236 on Defense of Mucosal Surfaces: Pathogenesis, Immunity and Vaccines, eds. Kraehenbuhl J-P and Neutra MR, pp.191-214.

9. Weitkamp J-H, Crowe JE Jr. Current approaches to vaccine development against disease caused by respiratory syncytial virus (RSV). Monatsschrift Kinderheilkunde (German Journal of Pediatrics) 2000; 148: 980-9.

10. Crowe JE Jr. The influence of maternal antibodies on neonatal immunization against respiratory viruses. Clinical Infectious Diseases 2001; 1720-7.

11. Crowe JE Jr., Suara RO, Brock S, Kallewaard N, House F, Weitkamp J-H. Genetic and structural determinants of virus neutralizing antibodies. Immunologic Reviews 2001; 23:135-45.

12. Pierson RN III, Crowe JE Jr, Pfeiffer S, Atkinson J, Azimzadeh, A, Miller GG. CD40L in primate cardiac allograft and viral immunity. Immunologic Reviews 2001; 23:253-62.

13. Crowe JE Jr. Respiratory syncytial virus vaccine development. Vaccine 2001; 20: S32-37.

14. Crowe JE Jr., Williams JV. Immunology of viral respiratory tract infection in infancy, Paediatric Respiratory Reviews 2003; 4:112-9.

Correspondence

Ho H-K, Principi N, Esposito S, Bosis S, Williams JV, Crowe JE Jr. Human metapneumovirus and lower respiratory tract disease in children. New England Journal of Medicine 2004; 350:1788-90.

Book Chapters

1. Murphy BR, Hall SL, Crowe JE Jr, Collins PL, Subbarao EK, Connors M, London WT, Chanock RM. The use of chimpanzees in respiratory virus research. In Erwin J, Landon JC, editors. Chimpanzee Conservation and Public Health: Environments for the Future. 1992; 21-8.

2. Crowe JE Jr, Murphy BR. Vaccines against respiratory syncytial virus and parainfluenza type 3, in New Generation Vaccines, 2nd edition, Levine MM, Woodrow GC, Kaper JB, Cobon GS. 1997; 711-25.

3. Crowe JE Jr, Englund JA. “Future Strategies for Prevention of Respiratory Syncytial Virus Infection,” in Contemporary Diagnosis and Management of Respiratory Syncytial Virus Infection, editors Weisman LE and Groothuis JR, 2000, pp 176-200.

4. Crowe JE Jr, Collins PL, Murphy BR. Chapter 52: Vaccines against respiratory syncytial virus and parainfluenza type 3, in New Generation Vaccines, 3rd edition, 2003, Levine MM, Kaper JB, Rappuoli R, Liu M, Good M, Marcel Dekker, pp. 621-40.

5. Crowe JE Jr, Weitkamp J-H, Williams JV. “B Cell Development”, Section XX, Developmental Immunobiology Chapter 155 in Polin /Fox/Abman: Fetal and Neonatal Physiology, 3rd edition, 2003, pp. 1518-22.

6. Lawton AR, Crowe JE Jr.“Ontogeny of Immunity”. Chapter 1 of Immunologic Disorders in Infants and Children, 5th edition, Eds. Stiehm, Ochs, Winkelstein, 2004, p3-19.

You are visiter number .